Yu-Wei Chen

Assistant Clinical Professor of Medicine

University of California, San Diego

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yu-Wei Chen is an Assistant Clinical Professor of Medicine at the University of California, San Diego, USA. His research focuses on cancer genomics, particularly in renal cell carcinoma and prostate cancer management, as evidenced by his recent publications on polygenic risk scores, immune infiltration, and the impact of COVID-19 vaccines on cancer patients. Additionally, he explores clinical trial methodologies and disparities in tumor mutation analysis, contributing significantly to the field of oncology.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Tian Zhang

University of Texas Southwestern

UNITED STATES

View details

Jungyoon Choi

Assistant Professor

St. Anne's University Hospital

SOUTH KOREA

View details

Nancy Davis

Associate Professor of Medicine & Urology

Vanderbilt University Medical Center

UNITED STATES

View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES

View details

Yeul Hong Kim

Seoul National University Hospital

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yu-Wei Chen

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT)

Recent Developments in the Management of Renal Cell Cancer

Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Polygenic Risk Scores Associated with Tumor Immune Infiltration in Common Cancers

Emerging Targets in Clear Cell Renal Cell Carcinoma

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.

Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration.

Collaborators (5)

Tian Zhang

Jungyoon Choi

Nancy Davis

Xingyi Guo

Yeul Hong Kim

Make your next move.